Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7507062 in Systemic Lupus Erythematosus
NCT05835986Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 1, open-label trial of RO7507062 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Roche. Primary endpoints: Dose Limiting Adverse Events at 29 days and Adverse Events at 12 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
RO7507062
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05835986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835986.